Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
- PMID: 9094648
- PMCID: PMC191523
- DOI: 10.1128/JVI.71.5.3734-3741.1997
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
Abstract
In the course of human immunodeficiency virus type 1 (HIV-1) infection, patients develop a strong and persistent immune response characterized by the production of HIV-specific antibodies. The aim of our study was to analyze the appearance of autologous and heterologous neutralizing antibodies in the sera of HIV-infected individuals. For this purpose, primary strains have been isolated from 18 HIV-1-infected subjects prior to seroconversion (in one case) or within 1 to 8 months after seroconversion. Sera, collected at the same time as the virus was isolated and at various times after isolation, have been analyzed for their ability to neutralize the autologous primary strains isolated early after infection, heterologous primary isolates, and cell-line adapted strains. Our neutralization assay, which combines serial dilutions of virus and serial dilutions of sera, is based on the determination of the serum dilution at which a fixed reduction in virus titer (90%) occurs. We have shown that (i) we could not detect autologous neutralizing antibodies in sera collected at the same time as we isolated viruses; (ii) we detected neutralizing antibodies against the autologous strains about 1 year after seroconversion, occasionally after 8 months, but sera were not always available to exclude the presence of neutralizing antibodies at earlier times; (iii) after 1 year, the neutralization response was highly specific to virus present during the early phase of HIV infection; and (iv) heterologous neutralization of primary isolates was detected later (after about 2 years). These results reveal the enormous diversity of neutralization determinants on primary isolates as well as a temporal evolution of the humoral response generating cross-reactive neutralizing antibodies.
Similar articles
-
Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.J Virol. 2000 Jun;74(12):5403-11. doi: 10.1128/jvi.74.12.5403-5411.2000. J Virol. 2000. PMID: 10823844 Free PMC article.
-
Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.J Acquir Immune Defic Syndr (1988). 1992;5(3):303-7. J Acquir Immune Defic Syndr (1988). 1992. PMID: 1740756
-
Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.J Infect Dis. 1994 Nov;170(5):1141-7. doi: 10.1093/infdis/170.5.1141. J Infect Dis. 1994. PMID: 7963706
-
Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro.AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):19-27. doi: 10.1089/aid.1997.13.19. AIDS Res Hum Retroviruses. 1997. PMID: 8989423
-
Antigenic variation of primate lentiviruses in humans and experimentally infected macaques.Immunol Rev. 1994 Aug;140:131-46. doi: 10.1111/j.1600-065x.1994.tb00868.x. Immunol Rev. 1994. PMID: 7821925 Review.
Cited by
-
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.J Virol. 2001 Oct;75(19):9177-86. doi: 10.1128/JVI.75.19.9177-9186.2001. J Virol. 2001. PMID: 11533181 Free PMC article.
-
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.J Virol. 2001 Nov;75(22):10892-905. doi: 10.1128/JVI.75.22.10892-10905.2001. J Virol. 2001. PMID: 11602729 Free PMC article.
-
A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.J Virol. 2003 Jun;77(12):6965-78. doi: 10.1128/jvi.77.12.6965-6978.2003. J Virol. 2003. PMID: 12768015 Free PMC article.
-
Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.J Virol. 2002 Oct;76(20):10299-306. doi: 10.1128/jvi.76.20.10299-10306.2002. J Virol. 2002. PMID: 12239306 Free PMC article.
-
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.J Virol. 2006 Jun;80(12):6155-64. doi: 10.1128/JVI.00093-06. J Virol. 2006. PMID: 16731954 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical